Energizing Rheumatology Training: Put Teaching Back into the Academic Limelight  
B.F. Mandell .................................................. 107

Immunoregulation in Idiopathic Inflammatory Myopathies: From Dendritic Cells to Immature Regenerating Muscle Cells  
A. Tournadre, P. Miossec ..................................... 110

Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results  
R.M. Fleischmann, A-M. Halland, M. Brzosko, et al. ........... 113

Comparative Effectiveness of Nonbiologic versus Biologic Disease-modifying Anti-rheumatic Drugs for Rheumatoid Arthritis  
E.M. DeWitt, Y. Li, J.R. Curtis, et al. .......................... 127

Cost-related Medication Nonadherence in Older Patients with Rheumatoid Arthritis  
L.R. Harrold, B.A. Briesacher, D. Peterson, et al. .............. 137

Investigation of Rheumatoid Arthritis Genetic Susceptibility Markers in the Early RA Study Further Replicates the TRAF1 Association with Radiological Damage  
S. Viatte, D. Plant, M. Lunt, et al. .............................. 144

Mycobacterial Interferon-γ Release Variations During Long-term Treatment with Tumor Necrosis Factor Blockers: Lack of Correlation with Clinical Outcome  
R. Scrivo, I. Sauzullo, F. Mengoni, et al. ........................ 157

Superiority of a High Loading Dose of Cholecalciferol to Correct Hypovitaminosis D in Patients with Inflammatory/Autoimmune Rheumatic Diseases  
P.P. Sainaghi, M. Bellan, A. Nerviani, et al. ........................ 166

Identification of Immunogenic HLA-B27:05 Binding Peptides of Salmonella Outer Membrane Protein in Patients with Reactive Arthritis and Undifferentiated Spondyloarthritis  
A.K. Singh, A. Aggarwal, S. Chaurasia, R. Misra ................ 173

Fascin-expressing Dendritic Cells Dominate in Polymyositis and Dermatomyositis  
H. Gende-Kubiak, E.G. Gendeck .............................. 186

Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept  
N. Solari, E. Palmisani, A. Consolaro, et al. .................... 192

Childhood Scurvy: A Pediatric Rheumatology Perspective  
D.G. Rumsey, A.M. Rosenberg ............................... 201

Infection Risks During Longer-term Rituximab Therapy Change Over Time  
E. Besada, J.C. Nossent ................................. 203

Reply  
P. Roll, T. Dörner, H. Tony ........................................ 203

Neuropsychiatric Manifestations of Systemic Lupus Erythematosus  
C. Abud-Mendoza, D. Herrera-Van Oostdam, M.U. Martínez-Martínez ................................. 204

Reply  
E. Zirkzee, G. Steup-Beekman, T. Huizinga .................. 204

Rare Side Effects of Subcutaneous Methotrexate Therapy  
S. Kapoor .......................................................... 205

Reply  
R. Hassanzadeh, C. Mangan, J. France, S. Bawa .............. 205

Local Differences in Skin Autofluorescence May Not Reflect Similar Differences in Oxidative Stress Exposure  
M. Hettema, A.J. Smit ........................................... 206

Reply A.K. Murray, C.E.M. Griffiths, A. Herrick ................................. 206
Letter
Ustekinumab for Resistant Psoriatic Arthritis
D.E.J. Wallis, N.M. Waldron, E. Korendowych

Correction
Consensus Statements for the Use of Administrative Health Data in Rheumatic Disease Research and Surveillance
S. Bernatsky, L. Lix, S. O'Donnell, D. Lacaille, and the CANRAD Network

Meetings in Rheumatology